Skip to main content
. 2013 Jan 1;14(1):20–28. doi: 10.4161/cbt.22626

graphic file with name cbt-14-20-g1.jpg

Figure 1. Percentages of patients with elevated levels of each tumor marker. Percentages of patients with elevated levels of each tumor marker were calculated by clinical stages in all patients (A) and in HER2-negative (B), HER2-overexpressed (C) and HER2-unknown patients (D).